Related Experiment Video
Updated: Aug 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Recent developments in lipid-lowering therapy. Highlights from the Atorvastatin Landmark Program: Global
1Sandwell & West Birmingham Hospitals NHS Trust, Lyndon, West Midlands B71 4HJ, UK. prabirbanerjee@yahoo.co.uk
Abstract:
The Atorvastatin Landmark Program: Global Investigators Meeting III was held June 1-3, in Toronto, Canada. The purpose of the meeting was to update investigators on the current status of the clinical trials that encompass the Atorvastatin Landmark Program. The main objectives were the following: 1. To review the range of studies that comprise the Atorvastatin Landmark Program. 2. To communicate recently completed study results and discuss the current and future impact of the findings, both individually and collectively, on clinical practice and guideline recommendations. 3. To discuss how the program is anticipated to evolve, highlighting new therapeutic modalities.
Insights
The Atorvastatin Landmark Program reviewed clinical trial results to inform practice. Findings will guide future cardiovascular treatment guidelines and therapeutic strategies.
Area of Science:
- Cardiovascular Medicine
- Clinical Pharmacology
- Medical Research Strategy
Background:
- The Atorvastatin Landmark Program is a series of clinical trials investigating the effects of atorvastatin.
- The Global Investigators Meeting III convened to discuss the program's progress and findings.
Framework:
- Reviewing the scope of studies within the Atorvastatin Landmark Program.
- Communicating recently completed study results and their impact.
- Discussing the evolution of the program and new therapeutic approaches.
Implementation:
- Investigators convened in Toronto, Canada, from June 1-3.
- The meeting focused on updating participants on the status of ongoing clinical trials.
- Discussions centered on the collective and individual impact of study findings on clinical practice.
Implications:
- Study results are expected to influence clinical practice and guideline recommendations.
- The program's evolution may introduce new therapeutic modalities for cardiovascular disease management.
- Dissemination of findings aims to enhance the understanding and application of atorvastatin therapy.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Peripheral Artery Disease III: Interprofessional Care
Hypertension III: Clinical Manifestations and Diagnostic Studies
